Introduction Psychiatry is one of the medical disciplines that suffers most from a lack of
innovation in its therapeutic arsenal. Many failures in drug candidate trials can be explained …

The arsenal of drugs for psychiatry has been difficult to renew for several decades. Many
failures in therapeutic trials can be explained by poorly evaluated pharmacological …

Positron Emission Tomography (PET) can be used to quantify proteins of interest in the
brain, assess the function of these proteins, and quantify cerebral glucose metabolism and …

The goal of any early central nervous system (CNS) drug development program is always to
test the mechanism and not the molecule in order to support additional research investments …

Central nervous system (CNS) drug development poses some unique challenges for drug
developers in terms of drug delivery, assessment of target engagement, and observation of …

Molecular imaging methods such as positron emission tomography (PET) are increasingly
involved in the development of new drugs. Using radioactive tracers as imaging probes, PET …

Positron emission tomography (PET) is an extensively used nuclear functional imaging
technique, especially for central nervous system (CNS) and oncological disorders. Currently …

Emission tomography techniques and, in particular, positron emission tomography (PET)
enable the in vivo study of several physiological and neurochemical variables in human …

Positron Emission Tomography (PET) represents a major advance in neuroimaging
techniques enabling for the first time the quantitative acquisition of in. vivo pharmacological …

The need for innovation in research is leading to an increased use of imaging biomarkers,
which have shown to reduce timings and increase productivity, thus saving costs. PET and …